Furthermore, emerging anti-inflammatory therapies that target the NLRP3 inflammasome or organelle dysfunction represent promising avenues for mitigating inflammation and fibrosis, two key contributors to the progression of DKD. The gene discussed is NLRP3; the disease is diabetic kidney disease.